The effect of GLP-1R agonists liraglutide and exendin-4 was examined in vivo on CD-1, MCF-1, MDA-MB-468, MDA-MB-231, 4T1, LNCap, PANC-1, MIA PaCa-2, CT26, SKOV-3, and Apc(Min/+) cell lines expressed in cancers such as thyroid, breast, prostate, pancreatic, colon, ovarian, intestinal, and liver (Table 2). This evidence concerns the gene GLP1R and cancer.